Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2581-2600 of 3,900 trials

Heart Failure Risk: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin can lower the risk of heart failure and cardiovascular death in people at increased risk. This trial compares this combination to dapagliflozin alone.

Heart Failure Signs and Symptoms>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyInternal Medicine

Acute Myeloid Leukemia: Low Intensity Therapy Study

We are exploring whether a gentler treatment approach helps patients with relapse or refractory acute myeloid leukemia live longer and feel better compared to stronger therapies.

Acute Myeloid LeukemiaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Erectile Dysfunction: Botulinum Toxin Injection Study

We are testing a new injection treatment for men with erectile dysfunction that hasn't improved with standard medications. The study will help us understand its effectiveness and any side effects.

Erectile Dysfunction6-12 monthsEfficacy phase (II)Standard MedicinesUrology

Familial Hypercholesterolemia: Inclisiran vs. Alirocumab

We are comparing two new treatments, inclisiran and alirocumab, to standard therapy for children with heterozygous familial hypercholesterolemia. The goal is to see which treatment better lowers cholesterol levels and improves quality of life.

Heterozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyEndocrinology

Allergy Vaccine for Grass and Cupressaceae Allergies

We are studying a new vaccine for people with allergies to grasses and cupressaceae, including those with mild to moderate asthma. The trial aims to see if this vaccine is more effective and safe than a placebo during pollen season.

Pollen AllergyAllergic RhinitisAllergic AsthmaConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Severe Vitamin D Deficiency: New Treatment Study

We are investigating a new treatment for people with severe vitamin D deficiency to see if it effectively raises vitamin D levels compared to another option. The study will also look at safety and patient satisfaction.

Severe Vitamin D Deficiency≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Acute Myeloid Leukemia: SNDX-5613 with Chemotherapy

We are testing a new drug, SNDX-5613, combined with intensive chemotherapy for patients with AML who have certain genetic changes. The goal is to see if this combination improves treatment outcomes.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Systemic Sclerosis: Efgartigimod PH20 SC Study

We are testing a new treatment for adults with systemic sclerosis to see if it improves skin symptoms and overall health compared to a placebo. The study will also look at safety and how well the treatment works.

Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

B-Cell Lymphoma: TranspoCART19 T Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory B-cell lymphoma. The trial aims to evaluate the safety and effectiveness of this therapy in improving patient outcomes.

Relapsed or Refractory B-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atopic Dermatitis: Methylprednisolone Aceponate Ointment

We are comparing a new ointment for atopic dermatitis with an existing treatment and a placebo. The goal is to see how well it reduces skin symptoms like itching and redness.

Mild to Moderate Atopic Dermatitis>2 yearsSafety phase (I)Investigational MedicinesAllergologyDermatology

Multiple Sclerosis: Ocrelizumab Serum Monitoring

We are studying how blood levels of ocrelizumab affect treatment outcomes in people with relapsing-remitting and primary progressive multiple sclerosis. This research may help personalize therapy and improve patient care.

Multiple Sclerosis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurology

Dexmedetomidine for Pain Management in Pediatric Surgery

We are studying whether adding intravenous dexmedetomidine to local anesthesia helps reduce pain after surgery in children. This trial will also look at how it affects recovery and any side effects.

Loco-regional Anesthesia in Pediatric Surgery6-12 monthsEfficacy phase (II)Standard MedicinesPartially RemoteInternal MedicineOtolaryngologyPediatrics

OMX-0407 for Unresectable Solid Tumors

We are studying a new medication, OMX-0407, in patients with previously treated solid tumors to see how well it works and to find the safest dose. This trial will help us understand its effects on cancer response and patient quality of life.

Previously Treated Unresectable Solid Tumours>2 yearsSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Colon Cancer: New Treatment with PIPAC

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard treatments improves outcomes for patients with advanced colon cancer that has spread to the abdomen. This trial will help us understand its effects on survival and quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Hidradenitis Suppurativa: AVTX-009 Treatment Study

We are evaluating a new treatment, AVTX-009, for individuals with moderate to severe hidradenitis suppurativa. The goal is to see if it works better than a placebo and to check its safety.

Hidradenitis Suppurativa3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Subarachnoid Hemorrhage: EDV2209 Medication Study

We are investigating the safety and tolerability of a new medication, EDV2209, for patients with bleeding in the brain. This study compares the effects of EDV2209 to a placebo to see how it may help in recovery.

Subarachnoid Hemorrhage>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurology

T-Cell Acute Lymphoblastic Leukemia: OC-1 CAR T Therapy

We are studying the safety and effectiveness of OC-1 therapy for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma. This trial aims to understand how well the treatment works and its impact on patient survival.

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology